Beryl Drugs Ltd vs Divis Laboratories Ltd
A side-by-side comparison of Beryl Drugs Ltd (524606) and Divis Laboratories Ltd (DIVISLAB) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Divis Laboratories Ltd leads 524606 vs DIVISLAB on 12 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
Valuation
How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has reduced debt.", "Stock is trading at 1.09 times its book value", "Debtor days have improved from 79.1 to 39.5 days.", "Company's working capital requirements have reduced from 55.1 days to 39.3 days"]
- − ["Though the company is reporting repeated profits, it is not paying out dividend", "The company has delivered a poor sales growth of 6.60% over past five years.", "Promoter holding is low: 27.8%", "Company has a low return on equity of 6.42% over last 3 years."]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
- − ["Stock is trading at 12.8 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.